Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Loxo Oncology Inc (LOXO) Worthy of Your Portfolio?

Page 1 of 2

Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the activity of those successful funds in these small-cap stocks. In the following paragraphs, we analyze Loxo Oncology Inc (NASDAQ:LOXO) from the perspective of those successful funds.

Is Loxo Oncology Inc (NASDAQ:LOXO) a bargain? Prominent investors are altogether in a bullish mood. The number of bullish hedge fund positions advanced by 1 in recent months. There were 10 hedge funds in our database with LOXO positions at the end of the previous quarter. At the end of this article we will also compare LOXO to other stocks including Modine Manufacturing Co. (NYSE:MOD), Amarin Corporation plc (ADR) (NASDAQ:AMRN), and TETRA Technologies, Inc. (NYSE:TTI) to get a better sense of its popularity.

Follow Loxo Oncology Inc. (NASDAQ:LOXO)
Trade (NASDAQ:LOXO) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

people, person, lab, nuclear, hydrogen, concept, chemistry, technicians, researching, formula, chemists, biotechnology, researchers, discovery, weapon, samples,

Syda Productions/Shutterstock.com

Keeping this in mind, let’s check out the recent action encompassing Loxo Oncology Inc (NASDAQ:LOXO).

How have hedgies been trading Loxo Oncology Inc (NASDAQ:LOXO)?

At Q3’s end, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this stock, a growth of 10% from the second quarter of 2016. The graph below displays the number of hedge funds with bullish position in LOXO over the last 5 quarters. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

loxo

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Dennis Purcell’s Aisling Capital has the biggest position in Loxo Oncology Inc (NASDAQ:LOXO), worth close to $105.5 million, amounting to 21.7% of its total 13F portfolio. Coming in second is OrbiMed Advisors, led by Samuel Isaly, which holds a $45.2 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Remaining members of the smart money that are bullish comprise Phill Gross and Robert Atchinson’s Adage Capital Management, John Paulson’s Paulson & Co and Richard Driehaus’ Driehaus Capital. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2
Loading...